Skip to content

Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2)

Homo sapiens — UniProt Q9Y6D5

Gene: ARFGEF2Homo sapiensSwissProt reviewed

Data last refreshed: (UniProt release unknown)

Key facts

Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2) is a protein from Homo sapiens identified by UniProt accession Q9Y6D5, 1785 residues long. MolForge cross-references it against 0 known binders and 104 disease associations.

  • UniProt accession: Q9Y6D5; gene symbol ARFGEF2.
  • Organism: Homo sapiens.
  • Length: 1785 amino acids.
  • Top disease associations (Open Targets): nodular neuronal heterotopia, periventricular nodular heterotopia and genetic disorder.
  • 3D structure: AlphaFold model available.

Target properties

Protein nameBrefeldin A-inhibited guanine nucleotide-exchange protein 2
UniProt accessionQ9Y6D5
GeneARFGEF2
OrganismHomo sapiens
Length1785 residues
Molecular weight—
EC numbers—
Target class—
Subcellular location—
Keywords—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tierMEDIUM
Druggability score—
Pocket score—
Max clinical phase—

Disease associations (104)

Diseases linked to this target (Open Targets).

  • nodular neuronal heterotopia · score 0.62
  • periventricular nodular heterotopia · score 0.46
  • genetic disorder · score 0.41
  • sex hormone-binding globulin measurement · score 0.31
  • Global developmental delay · score 0.29
  • neutrophil count · score 0.27
  • Seizure · score 0.26
  • Hydrocephalus · score 0.26
  • glioblastoma multiforme · score 0.25
  • lung adenocarcinoma · score 0.25

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

StructureSourceMethodMean pLDDTResolution (Å)
AF-Q9Y6D5-F1alphafoldPREDICTED76.82—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6D5.

Amino-acid sequence (1785 residues)

MQESQTKSMF VSRALEKILA DKEVKRPQHS QLRRACQVAL DEIKAEIEKQ RLGTAAPPKA NFIEADKYFL PFELACQSKS PRVVSTSLDC LQKLIAYGHI TGNAPDSGAP GKRLIDRIVE TICSCFQGPQ TDEGVQLQII KALLTAVTSP HIEIHEGTIL QTVRTCYNIY LASKNLINQT TAKATLTQML NVIFTRMENQ VLQEARELEK PIQSKPQSPV IQAAAVSPKF VRLKHSQAQS KPTTPEKTDL TNGEHARSDS GKVSTENGDA PRERGSSLSG TDDGAQEVVK DILEDVVTSA IKEAAEKHGL TEPERVLGEL ECQECAIPPG VDENSQTNGI ADDRQSLSSA DNLESDAQGH QVAARFSHVL QKDAFLVFRS LCKLSMKPLG EGPPDPKSHE LRSKVVSLQL LLSVLQNAGP VFRTHEMFIN AIKQYLCVAL SKNGVSSVPD VFELSLAIFL TLLSNFKMHL KMQIEVFFKE IFLNILETST SSFEHRWMVI QTLTRICADA QCVVDIYVNY DCDLNAANIF ERLVNDLSKI AQGRSGHELG MTPLQELSLR KKGLECLVSI LKCMVEWSKD LYVNPNHQTS LGQERLTDQE IGDGKGLDMA RRCSVTSMES TVSSGTQTTV QDDPEQFEVI KQQKEIIEHG IELFNKKPKR GIQFLQEQGM LGTSVEDIAQ FLHQEERLDS TQVGDFLGDS ARFNKEVMYA YVDQLDFCEK EFVSALRTFL EGFRLPGEAQ KIDRLMEKFA ARYIECNQGQ TLFASADTAY VLAYSIIMLT TDLHSPQVKN KMTKEQYIKM NRGINDSKDL PEEYLSSIYE EIEGKKIAMK ETKELTIATK STKQNVASEK QRRLLYNLEM EQMAKTAKAL MEAVSHAKAP FTSATHLDHV RPMFKLVWTP LLAAYSIGLQ NCDDTEVASL CLEGIRCAIR IACIFGMQLE RDAYVQALAR FSLLTASSSI TEMKQKNIDT IKTLITVAHT DGNYLGNSWH EILKCISQLE LAQLIGTGVK TRYLSGSGRE REGSLKGHTL AGEEFMGLGL GNLVSGGVDK RQMASFQESV GETSSQSVVV AVDRIFTGST RLDGNAIVDF VRWLCAVSMD ELASPHHPRM FSLQKIVEIS YYNMNRIRLQ WSRIWHVIGD HFNKVGCNPN EDVAIFAVDS LRQLSMKFLE KGELANFRFQ KDFLRPFEHI MKKNRSPTIR DMAIRCIAQM VNSQAANIRS GWKNIFAVFH QAASDHDGNI VELAFQTTCH IVTTIFQHHF PAAIDSFQDA VKCLSEFACN AAFPDTSMEA IRLIRFCGKY VSERPRVLQE YTSDDMNVAP GDRVWVRGWF PILFELSCII NRCKLDVRTR GLTVMFEIMK SYGHTFEKHW WQDLFRIVFR IFDNMKLPEQ LSEKSEWMTT TCNHALYAIC DVFTQFYEAL NEVLLSDVFA QLQWCVKQDN EQLARSGTNC LENLVISNGE KFSPEVWDET CNCMLDIFKT TIPHVLLTWR PVGMEEDSSE KHLDVDLDRQ SLSSIDKNPS ERGQSQLSNP TDDSWKGRPY ANQKLFASLL IKCVVQLELI QTIDNIVFYP ATSKKEDAEH MVAAQQDTLD ADIHIETEDQ GMYKYMSSQH LFKLLDCLQE SHSFSKAFNS NYEQRTVLWR AGFKGKSKPN LLKQETSSLA CCLRILFRMY VDENRRDSWE EIQQRLLTVC SEALAYFITV NSESHREAWT SLLLLLLTKT LKINDEKFKA HASMYYPYLC EIMQFDLIPE LRAVLRKFFL RIGVVYKIWI PEEPSQVPAA LSPVW

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with ARFGEF2?

The strongest Open Targets associations for ARFGEF2 are nodular neuronal heterotopia, periventricular nodular heterotopia, genetic disorder, sex hormone-binding globulin measurement and Global developmental delay.

How long is the ARFGEF2 protein?

The Homo sapiens ARFGEF2 protein (UniProt Q9Y6D5) is 1785 amino acids long.

Browse: Targets: A · all protein targets A–Z · drugs A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Explore Brefeldin A-inhibited guanine nucleotide-exchange protein 2 with MolForge

Find binders, run structure-based screening, and map this target across diseases and approved drugs with our AI-powered platform.

Browse all targets

Quick facts

UniProtQ9Y6D5
GeneARFGEF2
OrganismHomo sapiens
Length1785
Binders0
Diseases104
View on UniProt